Silexion Therapeutics Corp (NASDAQ:SLXN) Stock Short Interest Jumps 1,545.5%

Silexion Therapeutics Corp (NASDAQ:SLXN) was the target of a significant increase in short interest in the month of September. As of September 15th, there was short interest totaling 238,617 shares, an increase of 1,545.5% from the August 31st total of 14,501 shares. Currently, 4.3% of the shares of the stock are sold short. Based on an average trading volume of 15,566,949 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analyst Weigh In

SLXN has been the topic of a number of analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Friday, September 11th. Maxim Group cut Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 29th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Silexion Therapeutics Trading Down 18.5%

Shares of NASDAQ:SLXN traded down $0.06 during midday trading on Thursday, reaching $0.26. 2,303,255 shares of the company’s stock traded hands, compared to its average volume of 12,627,722. The company has a fifty day simple moving average of $0.98 and a two-hundred day simple moving average of $5.13. Silexion Therapeutics has a 1 year low of $0.25 and a 1 year high of $42.60.

Silexion Therapeutics (NASDAQ:SLXN) last issued its quarterly earnings results on Saturday, August 15th. The company reported ($5.17) EPS for the quarter, topping the consensus estimate of ($21.20) by $16.03. On average, equities research analysts forecast that Silexion Therapeutics will post -4.7 earnings per share for the current fiscal year.

Silexion Therapeutics Company Profile

Silexion Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company focused on developing RNA-based treatments for solid tumors driven by mutations in the KRAS gene. The company’s research is centered on gene-silencing technologies designed to inhibit KRAS, an important cancer-promoting protein that has historically been difficult to target with conventional therapies.

Silexion’s development programs include SIL-204, an investigational small interfering RNA (siRNA) therapy designed to target KRAS mutations, including KRAS G12D, a frequently observed mutation in pancreatic cancer.